Clinical Report: Elevated Risk of Lymphoma in Patients Exhibiting Systemic Symptoms of Sjögren’s Disease

Overview

This study evaluates the clinical and immunological characteristics of patients with primary Sjögren’s disease (pSjD) and highlights the elevated risk of lymphoma, particularly in those with systemic involvement. The findings underscore the importance of stratifying pSjD based on disease phenotype.

Background

Sjögren’s disease is a chronic autoimmune disorder that can lead to significant morbidity, including an increased risk of lymphoma. Understanding the differences between glandular and systemic phenotypes of pSjD is crucial for patient management and early detection of complications such as lymphoma.

Data Highlights

Key Findings

• 53% of patients had a glandular phenotype, while 47% had a systemic phenotype.
• Sicca symptoms were prevalent in both groups (xerophthalmia 89%, xerostomia 84%).
• Systemic involvement was associated with higher ESSDAI scores (13.9 vs. 4.0; p < 0.001).
• Lymphoma developed in 5% of patients, predominantly in those with systemic involvement (10% vs. 1%; p = 0.001).
• Immunosuppressive therapy was more commonly used in patients with systemic involvement.

Clinical Implications

Clinicians should closely monitor patients with systemic pSjD for signs of lymphoma, given the significantly higher incidence in this group. Stratification based on disease phenotype is essential for effective management and early intervention.

Conclusion

The findings emphasize the need for careful classification of pSjD and highlight the importance of vigilant follow-up in patients with systemic manifestations to facilitate early lymphoma detection.

Related Resources & Content

1. Author(s)/Org, Source, Year -- Elevated Risk of Lymphoma in Patients Exhibiting Systemic Symptoms of Sjögren’s Disease
2. Clinical Rheumatology — Frequency of Sjögren’s Syndrome in Patients with Rheumatoid Arthritis in the United States: Insights from the Corrona Registry Observational Study
3. Ophthalmology Management — WHEN Dry Eye Isn’t Just DRY EYE
4. Contact Lens Spectrum — THE SJOGREN'S PARADOX
5. Frontiers in Reproductive Health — Adverse pregnancy outcomes and risk factors in women with primary Sjögren's syndrome: data from a prospective study
6. Frequency of Sjögren’s Syndrome in Patients with Rheumatoid Arthritis in the United States: Insights from the Corrona Registry Observational Study
7. WHEN Dry Eye Isn’t Just DRY EYE
8. THE SJOGREN'S PARADOX
9. High incidence of lymphoma in Sjögren's disease: predictors and mortality implications in a prospective cohort study
10. 2024 British Society for Rheumatology guidelines
11. Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren’s disease | Novartis